AbbVie (NYSE: ABBV) is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff ...

Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

In contrast, last year's second highest sales product, AbbVie's autoimmune disease treatment 'Humira,' fell out of the top 10 due to the emergence of generic drugs after its patent expiration.

AbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will continue to lose market share to biosimilars. Revenue from Humira declined 35.9% in the first quarter, AbbVie reported.

Shares in the pharma company fell more than 8% after it reported sales of immunology therapy Humira (adalimumab) came in at $3.5 billion – down 25% – while new therapies Skyrizi (risankizumab ...

The company expects Humira's annual sales to stabilize between $4 billion and $5 billion post-exclusivity loss, a substantial decline from its peak. This erosion puts pressure on AbbVie to rapidly ...

This could lead to a more rapid decline in Humira sales than currently projected, potentially impacting AbbVie's ability to offset losses with growth from other products in its portfolio.